Role of ERCC5 polymorphisms in non‑small cell lung cancer risk and responsiveness/toxicity to cisplatin‑based chemotherapy in the Chinese population

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. Cisplatin-based chemotherapy currently represents the main treatment option for patients with NSCLC. The aim of the present study was to evaluate effect of single nucleotide polymorphisms (SNPs) within the excision repair cross-complementing group 5 (ERCC5) gene on susceptibility to NSCLC, as well as the responsiveness to and toxicity of cisplatin chemotherapy. A total of 506 patients with NSCLC and 510 healthy controls were recruited for the present study. All DNA samples were genotyped by the Agena MassARRAY platform. Logistic regression analysis was carried out to assess the relationship between ERCC5 polymorphisms with NSCLC susceptibility and responsiveness to chemotherapy. The rs4771436 TG-GG genotype was associated with increased NSCLC risk. When the data were stratified according to age, sex, tobacco smoking, body mass index and histological type, ERCC5 polymorphisms (rs2016073, rs4771436, rs11069498 and rs4150330) were associated with NSCLC risk. Furthermore, the A allele and GA-AA genotype of rs11069498 were related to the response to chemotherapy. ERCC5 (rs11069498 and rs4150330) polymorphisms were associated with the increased risk of toxicity. However, rs4771436 in ERCC5 gene was significantly correlated with the reduced risk of toxicity. These results suggested a potential relationship between ERCC5 polymorphisms, the risk of NSCLC and the sensitivity to cisplatin-based chemotherapy among Chinese populations.

[Retracted] Clinical Efficacy and Safety Analysis of PD‐1/PD‐L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non‐Small‐Cell Lung Cancer: A Systematic Review and Meta‐Analysis

“…Metaanalysis results showed that pembrolizumab combined with chemotherapy improved 1-year survival rate and prolonged OS, with statistically significant differences compared with chemotherapy alone, while complete response rate, PFS, and chemotherapy alone showed no statistically significant differences. Relevant studies [36][37][38] also showed that pembrolizumab combined with chemotherapy had a higher proportion of grade 3 and 4 leukopenia, rash, and infusion reaction than chemotherapy alone, and the difference was statistically significant, but there was no increase in the mortality rate. Therefore, pembrolizumab is effective and safe.…”

A novel DNA damage repair gene-related prognostic model for evaluating the prognosis and tumor microenvironment infiltration of esophageal squamous cell carcinoma

“…A recent study demonstrated that ERCC5 (key components of the nucleotide excision repair pathway) was remarkably associated with susceptibility to tumors[ 31 ]. Li et al reported that ERCC5 was significantly associated with the response of cisplatinbased chemotherapy of non-small cell lung cancer[ 32 ]. Another study reported that the expression level of ERCC5 was significantly increased in hepatocellular carcinoma, and high ERCC5 expression conferred poor prognosis[ 33 ].…”

High expression of transcription factor POU2F1 confers improved survival on smokers with lung adenocarcinoma: a retrospective study of two cohorts

“…Other than KRAS, most of the smokingassociated mutations comprise loss-of-function of tumorsuppressive deoxyribonucleic acid (DNA)-damage repair genes, such as excision repair complementary complex 5 and 8 (ERCC5, ERCC8), DNA ligase 4 (LIG4), mutY DNA glycosylase (MUTYH), DNA polymerase beta (POLB), DNA repair protein REV1 as well as G/T mismatchspecific thymine DNA glycosylase (TDG) (9). While some of these genetic aberrations might predict responsiveness to platinum-based chemotherapies (13)(14)(15)(16), none of them have been translated into targeted NSCLC therapies yet. Thus, discovery of novel targets for the treatment of smokingrelated lung cancer is of primary importance.…”